Stocks · News reference
J.P. Morgan and Rodman & Renshaw Initiate Coverage on Hemab Therapeutics Holdings, Inc.
J.P. Morgan and Rodman & Renshaw have initiated research coverage on Hemab Therapeutics Holdings, Inc. with positive ratings and specific price targets.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
JP Morgan Initiates Coverage On Hemab Therapeutics Hldgs with Overweight Rating, Announces Price Target of $70
Rodman & Renshaw Initiates Coverage On Hemab Therapeutics Hldgs with Buy Rating, Announces Price Target of $56
Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy rating and announces Price Target of $56.